-

Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, and Gudarz Davar, M.D., chief medical officer, will present a company overview at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023 at 3:30 p.m. ET.

A live webcast of the presentation can be accessed online here and a replay will be available for 90 days following the presentation.

About Autobahn Therapeutics

Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, and Will Stratton, SVP Corporate Development, Strategy, and Planning, will participate in the 2025 Jefferies London Healthcare Conference being held November 17-20, 2025, in London, UK. About Autobahn Therapeutics Autobahn Therapeutics is a bio...

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that management will participate in the following upcoming investor conferences in September: 2025 Cantor Global Healthcare Conference Investor Meetings: Wednesday, September 3, 2025 Location: New York, NY 2025 BofA Healthcare Trailblazers Private Company Conference Investor Meetings: Wednesday, Septe...

Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Will Stratton, VP, Corporate Development, Strategy, and Planning, will participate in Evercore’s Emerging Private Biotech Conference being held July 13-15, 2025, in Newport, RI. About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric...
Back to Newsroom